Beijing Immunochina Pharmaceutical Co., Ltd, a developer of innovative gene and cell therapies for malignant tumors, has completed its Series D round, raising ‘tens of millions of US dollars’.

艺妙神州，北京艺妙神州医药科技有限公司，北京艺妙神州医疗科技有限公司，CAR-T，何霆，自体CAR-T，通用型CAR-T，异体CAR-T，实体瘤，血液瘤，免疫治疗，IND，新药临床试验批件，注册临床，研究者发起的临床研究，IIT，CAR-T药物筛选体系，质粒制备体系，慢病毒载体制备，原代免疫细胞制备，CD19，IM19，GPC3，InnovaCART，DuraCART，HPCART，UCART，基因细胞药物，肿瘤治疗，癌症，非霍奇金淋巴瘤，急性B淋巴细胞白血病，套细胞淋巴瘤，肝细胞癌，黑色素瘤

Immunochina Nets Over $15M In Series D

Description

Company Information

Funding Insights

Immunochina Nets Over $15M In Series D

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information